HIPEC in recurrent ovarian cancer: flogging a tired HORSE?
作者信息
Bhatt Aditi, Kazi Mufaddal, Bhandoria Geetu, Seshadri Ramakrishnan Ayloor
机构信息
Department of Surgical Oncology, Shalby Cancer and Research Institute, Ahmedabad, India.
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India.
出版信息
J Gynecol Oncol. 2025 Mar;36(2):e90. doi: 10.3802/jgo.2025.36.e90. Epub 2025 Mar 10.
Abstract
摘要
相似文献
1
HIPEC in recurrent ovarian cancer: flogging a tired HORSE?
J Gynecol Oncol. 2025 Mar;36(2):e90. doi: 10.3802/jgo.2025.36.e90. Epub 2025 Mar 10.
2
Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review.
Int J Gynecol Cancer. 2016 May;26(4):661-70. doi: 10.1097/IGC.0000000000000664.
3
Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
ESMO Open. 2022 Oct;7(5):100586. doi: 10.1016/j.esmoop.2022.100586. Epub 2022 Sep 16.
4
The role of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in ovarian carcinoma: where do we stand today? A comprehensive review and clinical insights from a leading oncology center in India.
World J Surg Oncol. 2025 Jun 11;23(1):232. doi: 10.1186/s12957-025-03869-0.
5
Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods.
Int J Gynecol Cancer. 2024 Jan 5;34(1):1-9. doi: 10.1136/ijgc-2023-004658.
6
Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.
J Cancer Res Clin Oncol. 2009 Dec;135(12):1637-45. doi: 10.1007/s00432-009-0667-4. Epub 2009 Aug 23.
7
Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized control trials.
Eur J Surg Oncol. 2025 Sep 2;51(11):110424. doi: 10.1016/j.ejso.2025.110424.
8
Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a systematic review and updated meta-analysis.
J Egypt Natl Canc Inst. 2025 Apr 30;37(1):28. doi: 10.1186/s43046-025-00286-y.
9
Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer.
JAMA Netw Open. 2025 Jun 2;8(6):e2517676. doi: 10.1001/jamanetworkopen.2025.17676.
10
Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study.
J Formos Med Assoc. 2025 Aug;124(8):746-751. doi: 10.1016/j.jfma.2024.08.014. Epub 2024 Aug 20.
本文引用的文献
1
Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
J Clin Oncol. 2025 Mar;43(7):852-860. doi: 10.1200/JCO.24.00686. Epub 2024 Nov 21.
2
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2024 Dec;25(12):1551-1562. doi: 10.1016/S1470-2045(24)00531-X. Epub 2024 Nov 14.
3
A narrative review of what can HIPEC do.
Eur J Surg Oncol. 2023 Sep;49(9):106976. doi: 10.1016/j.ejso.2023.07.002. Epub 2023 Jul 8.
4
Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer.
Cancers (Basel). 2023 Jul 6;15(13):3519. doi: 10.3390/cancers15133519.
5
Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
Gynecol Oncol. 2022 Dec;167(3):547-556. doi: 10.1016/j.ygyno.2022.10.010. Epub 2022 Oct 20.
6
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294.
7
Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer.
Front Oncol. 2021 Sep 23;11:674637. doi: 10.3389/fonc.2021.674637. eCollection 2021.
8
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
J Clin Oncol. 2021 Aug 10;39(23):2594-2604. doi: 10.1200/JCO.21.00605. Epub 2021 May 21.
9
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8.
10
The concept of "Obstruction-Free Survival" as an outcome measure in advanced colorectal cancer management.
Pleura Peritoneum. 2018 Feb 28;3(1):20180101. doi: 10.1515/pp-2018-0101. eCollection 2018 Mar 1.
Zotero 插件